JP2019504101A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504101A5
JP2019504101A5 JP2018540793A JP2018540793A JP2019504101A5 JP 2019504101 A5 JP2019504101 A5 JP 2019504101A5 JP 2018540793 A JP2018540793 A JP 2018540793A JP 2018540793 A JP2018540793 A JP 2018540793A JP 2019504101 A5 JP2019504101 A5 JP 2019504101A5
Authority
JP
Japan
Prior art keywords
acamprosate
piperazin
phenylsulfonyl
quinoline
baclofen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504101A (ja
JP7027318B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/052470 external-priority patent/WO2017134280A1/en
Publication of JP2019504101A publication Critical patent/JP2019504101A/ja
Publication of JP2019504101A5 publication Critical patent/JP2019504101A5/ja
Application granted granted Critical
Publication of JP7027318B2 publication Critical patent/JP7027318B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540793A 2016-02-05 2017-02-03 神経障害の新規の併用療法 Expired - Fee Related JP7027318B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16305128.7 2016-02-05
EP16305128 2016-02-05
EP17152720.3 2017-01-23
EP17152720 2017-01-23
PCT/EP2017/052470 WO2017134280A1 (en) 2016-02-05 2017-02-03 Novel combinatorial therapies of neurological disorders

Publications (3)

Publication Number Publication Date
JP2019504101A JP2019504101A (ja) 2019-02-14
JP2019504101A5 true JP2019504101A5 (https=) 2020-03-12
JP7027318B2 JP7027318B2 (ja) 2022-03-01

Family

ID=58044028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540793A Expired - Fee Related JP7027318B2 (ja) 2016-02-05 2017-02-03 神経障害の新規の併用療法

Country Status (6)

Country Link
US (1) US10799499B2 (https=)
JP (1) JP7027318B2 (https=)
CN (1) CN109069450A (https=)
AU (1) AU2017216288B2 (https=)
CA (1) CA3012900A1 (https=)
WO (1) WO2017134280A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512174A (ja) * 2018-01-29 2021-05-13 ファーネクストPharnext アセチルコリンエステラーゼ阻害剤療法に対する反応性を失った患者におけるアルツハイマー病のバクロフェン及びアカンプロセートを用いた療法
US20220401404A1 (en) * 2019-02-05 2022-12-22 The Regents Of The University Of California Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection
CN114181201B (zh) * 2020-09-15 2023-12-01 香港科技大学 作为针对各种神经退行性疾病的潜在治疗剂的新化合物
WO2025151884A1 (en) * 2024-01-12 2025-07-17 Parsons C Lowell Use of glycosaminoglycan sulfated polysaccharides such as sodium pentosan polysulfate in combination with permeation agents to treat alzheimer's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20080206332A1 (en) * 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
JP2010521516A (ja) * 2007-03-21 2010-06-24 グラクソ グループ リミテッド 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用
EP2508177A1 (en) * 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
AU2009242126B2 (en) * 2008-04-29 2014-03-27 Pharnext New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
TR201809351T4 (tr) * 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis

Similar Documents

Publication Publication Date Title
US10434109B2 (en) Compositions for treating neurological disorders
JP5987008B2 (ja) バクロフェンおよびアカンプロセートに基づく神経疾患の治療
JP6619744B2 (ja) 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用
EA032881B1 (ru) Применение торасемида для лечения болезни альцгеймера или родственного болезни альцгеймера расстройства или травмы спинного мозга
US9931326B2 (en) Composition comprising torasemide and baclofen for treating neurological disorders
JP7027318B2 (ja) 神経障害の新規の併用療法
JP2019504101A5 (https=)
JP7065880B2 (ja) アルツハイマー病のイダロピルジン系組合せ療法
JP6430445B2 (ja) バクロフェンおよびアカンプロセートに基づく神経疾患の治療
EP3411025A1 (en) Novel combinatorial therapies of neurological disorders
HK1233960A1 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders